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Key Points:  
1. There is a distinct lack of age appropriate cardiotonic drugs and adult formulations are administered without 
evidence based knowledge on their dosing, safety, efficacy and long term effects.  
2. Dopamine remains the most commonly studied and prescribed cardiotonic drug in the neonatal intensive 
care unit (NICU), but evidence of its effect on end organ perfusion is still lacking.   
3. Unlike adult and paediatric critical care, there are significant gaps in knowledge on the use of various 
cardiotonic drugs in various forms of circulatory failure in the NICU.  
4. Performing clinical trials in this area has been challenging and highlights the need for international 
collaborations, the importance of synergy between the Food and Drug Administration (FDA) and European 
Medicines Agency (EMA), and the inclusion of industry in the conduct of such trials.  
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1. Introduction 
Inotrope/vasopressors are commonly used in the NICU but with wide variations in practice regarding indications, 
duration and dosing1,2. Following delivery neonates need to adapt their cardiorespiratory system from intrauterine to 
extrauterine life. During this transition phase, many additional factors can impact this process including timing of 
umbilical cord clamping, chorioamnionitis, inadequate oxygenation, relative adrenal insufficiency and infection, 
especially in the most extreme preterm neonates. These interrelated factors often result in a clinical picture 
characterized by low blood pressure which often is  treated with agents such as dopamine, dobutamine, 
noradrenaline, or corticosteroids3. 
None of these drugs are currently licensed for the use in preterm or term neonates in spite of the introduction of 
the Medicines in Children’s Acts in several countries 4. Due to lack of age appropriate formulations, many adult 
formulations are administered without evidence based knowledge on their safety, efficacy, long term effects of 
excipients and age appropriate dosing 5,6. Recently efforts have been initiated to address these deficiencies through 
funding large randomized trials of inotropes in newborns 7,8. 
Neonatal circulatory failure may occur in many settings.  Hypovolemic shock, an infrequent cause of hypotension 
in the immediate transition period, may be minimised by providing enhanced placental transfusion9-12.  A recent 
meta-analysis in preterm neonates receiving placental transfusion found an increased death rate (30%) if the cord 
was clamped immediately 13.  Long term follow up studies in preterm and term neonates have shown a good safety 
profile with improved neurodevelopmental outcomes up to 4 years of age 14-17. In term neonates, circulatory failure 
may occur in the setting of early onset sepsis, persistent pulmonary hypertension of the newborn, perinatal asphyxia, 
or as a result of complex congenital cardiac defects. Preterm neonates more often have difficulty in adapting their 
circulation to extra-uterine life during the first 72 hours of birth.  Additional causes for circulatory failure later during 
their hospital stay include sepsis, necrotizing enterocolitis, and patent ductus arteriosus.  
Defining  circulatory failure in the newborn  poses many challenges for clinicians. Traditionally  blood pressure 
has been the main criteria utilized to define the  adequacy of circulatory wellbeing.  Numerous blood pressure 
reference ranges exist, based on gestational age, birth weight and postnatal age.  Defining mean blood pressure 
values below a particular centile , or less than absolute values,  less than gestational age equivalent in mmHg has 
been the most popular definition 3,18 used, but this is too simplistic an approach. More recently other surrogate 
markers of circulatory failure have been considered, such as base excess and blood lactate as markers of poor tissue 
perfusion 19,20. Cardiac function and organ perfusion are now assessed by functional echocardiography, tissue 
Doppler, pulse plethysmography or near infrared spectroscopy (NIRS) 21. Treatment algorithms and guidelines often 
rely on preferences of local clinicians and their ability to use these additional assessment methods 5. While a number 
of groups continue to evaluate the role of  additional monitoring tools in haemodynamic assessment22-25, further 
evaluation and clinical trials are necessary before they are routinely incorporated into clinical practice26 ( see Figure 
1). In the following sections we review some of the most commonly prescribed drugs and the conditions in which 
they are used. 
 
2. Inotropic/ Vasopressors/ Inodilators   
Dopamine  
Dopamine is the most commonly used inotrope in the treatment of neonatal hypotension 27,28 and is certainly 
the most studied of all the cardiotonic drugs used in newborn care. There are numerous observational studies of its 
use in neonates and there are now over 20 randomised controlled trials comparing dopamine to other agents, 
including placebo. Dopamine works through stimulation of α and β adrenergic receptors and dopaminergic receptors. 
The results of these numerous observational studies is a number of postulated effects, suggesting a dose dependent 
effect  on different organs systems 29,30. The standard administration is by continuous infusion at doses of 2-20 
mcg/kg/min with the assumption being that the lower doses of 2-5 mcg/kg/min mainly affect the dopaminergic 
receptors31,32,. Further increasing the dose stimulates α adrenergic receptors causing vasoconstriction and increases 
in systemic vascular resistance33. Although this leads to an increase in cardiac contractility and output 28,34, evidence 
from randomised controlled trials suggests that dopamine may have a negative impact on cardiac output through an 
inotrope/vasopressor imbalance35-37. It would be too simple to state that above a certain level one effect is greater 
than the other, but certainly with increasing doses one is likely to see more vasopressor than inotrope effects and 
thus the potential to impair end organ perfusion becomes a reality. There is a great deal of overlap in these effects, 
particularly in critically ill neonates. The choice of an appropriate drug for a specific clinical condition depends on a 
number of complex interrelated factors including determinants of cardiovascular function and the underlying disease 
process. There are a number of studies that have assessed the pharmacokinetic (PK) and pharmacodynamic (PD) 
properties of dopamine in the paediatric population, some of these in neonates38-46. The methods of analysis have 
differed which may account for some of the variability across the studies.  The effects on systemic, pulmonary, and 
cerebral haemodynamics can be monitored at the bedside.  Echocardiographic assessment, in particular in the 
presence of a patent ductus arteriosus47,48 , has provided some insights into the systemic and pulmonary effects. NIRS 
has permitted a better understanding of the potential effects on cerebral oxygenation, blood flow, and 
autoregulation. It has been suggested that dopamine may have negative effects on the cerebrovascular 
autoregulatory capacity in very preterm neonates49 which has not been seen by others50. In a follow up study, 
neurodevelopmental outcome at three years may be worse in neonates treated with dopamine versus dobutamine51. 
In a meta-analysis of observational studies, dopamine not only increased BP but also cerebral blood flow52. There are 
no studies comparing dopamine versus placebo in neonates with low blood pressure including evaluating the effects 
on measures of cerebral perfusion/ cerebral oxygenation. Such studies are warranted.   
Dobutamine  
 
Dobutamine is often used as a second line inotropic agent if a maximum dose of dopamine has been 
reached27. It is a synthetic inotrope which directly stimulates α and β1 receptors in the myocardium. Dobutamine 
increases cardiac output by increasing contractility and heart rate. In addition, it can have a vasodilatory effect 
through stimulation of peripheral β2 receptors 53,54. Dobutamine is administered by continuous infusion with 
recommended doses of 5-20 mcg/kg/min. Several studies have compared dopamine with dobutamine for circulatory 
failure and most have demonstrated a greater increase in mean blood pressure with dopamine administration34,36,55.  
However, dobutamine has been observed to increase right and left ventricular output in comparison to dopamine. 
Comparative studies reported a 21% increase in left ventricular outflow with dobutamine and observed a 14% 
decrease with dopamine 35,36. Dobutamine has been shown to increase superior vena cava blood flow in comparison 
to both dopamine and placebo in neonates with low blood pressure. As with all studies of cardiotonic drugs, very 
little long term neurodevelopmental outcome data are available.  
 
Epinephrine 
Epinephrine (Adrenaline) is secreted by the adrenal medulla as an endogenous catecholamine. It stimulates α 
and β receptors. It is typically used in protracted neonatal hypotension if dopamine and dobutamine do not achieve 
the desired effects6. However, it is used as a first line agent by some as determined from surveys of practice 2,56. The 
effects on the circulation are generally dose dependent. At lower doses the stimulated β receptors cause vasodilation 
in the systemic and pulmonary circulations. It also increases heart rate and cardiac stroke volume. At increasing 
doses α receptors mediated effects are seen resulting in vasoconstriction 28.  The infusion should be administered 
through a central venous line with a dosing range of 0.05-1.0 mcg/kg/min. Higher doses of have been used but are 
not recommended57,58. 
There are very few randomised controlled studies of epinephrine in preterm neonates59 . Pellicer and 
colleagues compared dopamine  to epinephrine in preterm neonates with low blood pressure. The clinical effects and 
the side effect profile included  a significant increase in heart rate, serum glucose concentration, and rise in lactate 
after 24-36 hours of continuous infusion compared to dopamine60.  
 
Norepinephrine  
Norepinephrine is an endogenous catecholamine which is released from adrenergic nerve endings. It has 
strong stimulating effects on α and β1 receptors and weaker effects on β2 receptors. Noradrenaline has more potent 
α mediated effects compared to adrenaline which  results in vascular constriction with a subsequent increase in SVR 
and BP. It may be useful in septic shock, in order to correct the low SVR 61. Although a number of cohort studies have 
reported the effects of norepinephrine in preterm neonates62,63,   randomized controlled trials to confirm these 
findings  are lacking. Norepinephrine might have a role in treating circulatory failure in severe Persistent Pulmonary 
Hypertension of the Newborn due to a reported pulmonary vasodilator effect62. Administration should be via central 
venous access at doses of 0.02-1 mcg/kg/min.  
Milrinone  
Milrinone is a Type III phosphodiesterase inhibitor which acts directly on the myocardium through its 
inotrope and lusitrope effects. In addition, it can cause vasodilation in the systemic and pulmonary circulation which 
makes it a drug of choice for treatment of Persistent Pulmonary Hypertension64. In a comparative study of 
levosimendan versus milrinone in neonates undergoing cardiac surgery, cerebral tissue oxygenation measurements 
were similar for both groups during the immediate 24 hour postoperative phase65. In contrast, peripheral 
oxygenation showed an increase in the levosimendan group and a decrease in the milrinone group together with an 
increase in lactate. Serial assessments of cardiac function by echocardiography did not demonstrate any differences 
between both groups. 
There is limited evidence for use of milrinone in preterm neonates.  It did not prevent the development of a 
low flow state in high risk preterm neonates when compared to placebo66,67. While Halliday and colleagues found no 
benefit for prophylactic milrinone administration following PDA ligation in preterm neonates, others have found a 
possible benefit68-70. Dosing regimens vary, but milrinone is often started with a loading dose of 50 mcg/kg followed 
by a continuous infusion. There is one PK study which recommends a bolus infusion of 0.73 mcg/kg/min over 3 hours 
followed by a continuous infusion of 0.16 mcg/kg/min in preterm neonates71. Side effects of tachycardia and 
hypotension have been described, so it should be used cautiously in the setting of low blood pressure.  
 
Vasopressin 
Vasopressin is an endogenous peptide which is expressed in the hypothalamus. The initial prohormone 
preprovasopressin is converted to provasopressin and vasopressin in the pituitary gland.72It causes vasoconstriction 
through stimulation of vasopressin V1 receptors in smooth muscle. In addition, it has a vasodilatory effect on 
cerebral and renal arterioles by stimulation of vasopressin V2 receptors. Overall data on the use in preterm and term 
neonates is limited and mostly reported as case series 73-78. Dosing is by continuous infusion of 0.00001-0.003 
unit/kg/min. There is quite a variation in the literature regarding the appropriate dosing and bolus administration of 
2-20 mcg/kg every 4-6 hours has been reported. Due to the short half-life of 5-15 minutes, the effects last only for 
about 30-60 minutes. A recent pilot study in 20 very preterm neonates compared vasopressin to dopamine during 
the first 24 hours of life. Both agents resulted in similar increases in BP but with less tachycardia in the vasopressin 
group 79. However, more studies are needed before any recommendations can be made for its routine use in the 
preterm neonate. 
Levosimendan 
Levosimendan is used in adults with acute decompensated congestive heart failure. In neonates it has mainly 
been used in during cardiac surgery as an inodilator. Levosimendan acts as a calcium sensitizer. It binds to C cardiac 
troponin and enhances the sensitivity of contractile myofilaments to intracellular calcium in the cardiac muscle cells, 
thus improving myocardial contractility80,81 . It activates sarcolemnal K-sensitive adenosine triphosphate channels of 
vascular smooth muscle cells which has vasodilatory effects. It is thought to have protective effects on ischemia of 
brain and kidney tissue in neonates. Improved tissue oxygenation measured by NIRS has been reported in a cohort of 
 
neonates undergoing cardiac surgery.82,83 Infusion doses for neonates range from 0.1-0.2 mcg/kg/min. The potential 
benefits include increased cardiac output and cardiac index as well as  a decrease in heart rate and lactate levels 83. 
The side effects include hypotension which needs careful and continuous monitoring. There is no reliable data on the 
use of levosimendan in preterm neoantes and its use as such cannot be recommended at present. 
Despite their ongoing use there is surprisingly very little PK and PD data available on the drugs highlighted above. 
Table 2 provides a summary of the PK/PD studies on dopamine in the neonate. What is evident from this table is the 
lack of more recent PK/PD data, especially in the very preterm neonate. Smits and colleagues propose an outline on 
how to use haemodynamic and cerebral monitoring to study pharmacodynamics in neonates84. This sort of 
monitoring will aid in better understanding the effects of inotropes, especially on brain perfusion in very preterm 
neonates. Figure 1 provides an overview of these potential processes and mechanisms and the monitoring tools 
available.  
 
3. Treatment Scenarios 
There are a number of treatment categories in which cardiotonic drugs are administered to the neonate. These 
include, but are not limited to, the clinical situations outlined below and listed in Table 2. These categories were 
chosen since these are common situations in which the agents are prescribed in the NICU.   
  
3.1 Transitional Low Blood pressure in the Preterm Neonate 
 
The most common situation in which cardiotonic drugs are administered to neonates is in the first day of life, 
primarily in preterm neonates with evidence of low blood pressure85,86. Uncertainty remains over criteria used to 
define low blood pressure, criteria upon which to intervene, and what treatment strategy should be employed87. 
Currently, the majority interventions occur when the blood pressure is below a defined value for a certain period of 
time, with the most common cardiotonic drug administered being dopamine27.  This approach is primarily based on 
familiarity; dopamine has been used as the primary inotrope since the 1970’s and when administered will generally 
result in an increase in blood pressure, which has been the main focus of cardiovascular stability. This approach is 
now being questioned by many groups, with the focus shifting towards assessment of flow rather than blood 
pressure88,89.However, defining cardiovascular stability during transition remains a key challenge. In a recent 
observational study by Batton and colleagues which included over 360 preterm neonates born at less than 27 weeks 
gestation across 16 sites, almost 55% were treated for cardiovascular instability, with over 30% of neonates receiving 
a cardiotonic drug (mostly  dopamine)85.   
Although dopamine has been the subject of a number of systematic reviews52,90 and over  20 randomised 
controlled trials in neonates, significant uncertainty remains91. Most studies have been characterized by small 
numbers, heterogenous inclusion criteria, and limited short and long-term follow up. While data obtained from these 
studies is very informative, the limitations need to be acknowledged. A recent observational study by the Epipage 
group have highlighted the potential benefits of an interventional approach to low blood pressure during the 
transitional phase of adaptation, suggesting that neonates who receive an intervention are less likely to sustain brain 
injury compared to neonates who have an observational approach to care only92. It is fair to say that this complex 
problem remains unresolved, but a number of ongoing or planned studies in this area may shed further light on the 
problem in the future.  
 
 
3.2 Pulmonary Hypertension (PH) 
 
While the incidence of PH seems to have decreased, and improved management strategies have resulted in fewer 
neonates requiring more extensive interventions, PH remains a significant problem in newborn care. Supporting the 
cardiorespiratory system in the setting of PPHN is primarily based on the use of nitric oxide, and the evidence 
suggests that the number needed to treat to prevent one neonate requiring ECMO is low (five)93. However, there is 
limited data on the use of various cardiotonic agents in the setting of PPHN94. The effect of each agent on systemic 
and pulmonary vascular resistance as well as ductal and atrial shunting needs to be considered. Finally the effects on 
he the peripheral vasculature, in particular cerebral vasculature, also needs to be considered. There is currently no 
obvious first line agent and the appropriate choice of first line inotropes/inodilators/lusitrope remains unclear. 
The role of echocardiography in the setting of PPHN is crucial, both to determine the extent of the problem 
and also to determine the effect of various intervention strategies95.  Animal data suggest that epinephrine may be a 
more suitable agent than dopamine as it has a relatively lower increase in pulmonary vascular resistance compared 
to dopamine96. However, norepinephrine may be a better alternative. The use of milrinone has increased significantly 
in the NICU97, primarily in the setting of PPHN. Although there are a number of case reports and case series, there are 
no randomized controlled trials addressing the use of milrinone in the setting of PPHN 98-100. There is currently one 
small pilot trial enrolling and a larger planned study of milrinone in the setting of congenital diaphragmatic hernia. 
However, it should be noted that enrollment into such studies may prove difficult.  A recent multisite randomized 
trial of bosentan in the setting of PPHN failed to enroll sufficient numbers of neonates101.   The reasons included the 
changing clinical spectrum and difficulties in obtaining timely informed consent. These challenges have afflicted a 
number of other studies in the area of cardiovascular support and will be discussed in a later section.  
 
 3.3 Cardiovascular Instability in the Setting of Sepsis 
Sepsis remains a common problem in newborn care, predominantly in low resource settings. Septic shock is a 
condition of inadequate tissue perfusion secondary to cardiovascular dysfunction occurring with suspected or certain 
systemic infection. It is interesting to note the recent guidance provided by the Surviving Sepsis Campaign. The 
algorithm addresses a goal directed approach to therapy and the initial inotrope suggested is dopamine I If resistant 
to therapy, epinephrine should be administered. However, there is very limited evidence to support such an 
approach, and we would suggest than an alternative approach be given consideration. There have been a number of 
 
trials in the paediatric population, from one month of age upwards comparing dopamine to epinephrine in the 
setting of sepsis. The consistent finding in this age group is that epinephrine is associated with improved survival in 
fluid refractory hypotensive shock102. Another consideration is the effect of sepsis on drug PK/PD. This is not well 
understood in the neonate and undoubtedly an individualized approach with particular dosing regimens needs to be 
carefully considered.  One recent trial compared epinephrine and dopamine as a first-line vasoactive drug in 40 
neonates with fluid-refractory septic shock in a low resource setting103. The initial starting dose of epinephrine was 
0.2 μg/kg/min and dopamine 10 μg/kg/min, with subsequent increases of each agent depending on the response. 
All-cause mortality by 28 days was very high (70%) in the epinephrine vs  dopamine group (80%)  . The authors 
concluded that epinephrine (0.2–0.4 μg/kg/min) and dopamine (10–20 μg/kg/min) had comparable efficacy and 
safety in neonatal septic shock. However mortality was extremely high and generalizability of these findings needs 
to be interpreted cautiously.  
3.4 Cardiovascular Instability in the Setting of Perinatal Asphyxia and Therapeutic Hypothermia 
 
The definition of perinatal asphyxia is broad but typically characterized by evidence of metabolic acidosis, low 
Apgar scores, and the need for initial respiratory support. The primary insult can have implications for cardiovascular 
function, often in the setting of multiorgan dysfunction.   Echocardiography findings after asphyxia include decreased 
contractility and cardiac output, impaired end diastolic filling, and increased pulmonary artery pressure.  The 
presence of some cardiac biomarkers is associated with altered echocardiographic findings. For neonates with 
evidence of clinical encephalopathy in the setting of perinatal asphyxia, the primary therapy is therapeutic 
hypothermia. This has been associated with a reduction in heart rate, stroke volume, and cardiac output and an 
increase in PH104-107.  However, these changes do not seem to be associated with an increase in mortality or adverse 
neurodevelopmental outcome in a meta-analysis of various trials of cooling strategies compared to controls.  
Therapeutic strategies include use of various agents such as dopamine, dobutamine and epinephrine. There is no 
consensus as to which agent may be the most appropriate and the majority of the current evidence available is 
derived from animal studies108,109.   
4. Administration of Agents  
  There are no neonatal specific cardiotonic formulations and this presents significant challenges, particularly 
in very preterm neonates where effective and timely delivery of an inotrope infusion may be crucial. There are many 
problems with the current use of adult preparations. A ready to use neonatal formulation means avoidance of 
unnecessary delays in formulation preparation.  It would also avoid unnecessary dilutions which are both time 
consuming and also increase the likelihood of contamination or a drug error.  Stability testing would be needed with 
neonatal specific formulations to ensure that the solution has an equal distribution of the drug as opposed to the 
current method which involves dilutions where there may be unequal distribution resulting in a risk of boluses of 
drug being administered.  These problems can only be overcome with the use of specific ready to use neonatal 
formulations.  
Even with the use of neonatal specific formulations, other administration challenges include very low 
infusion rates and relatively large dead space considerations which will result in long lag times before the drug gets 
to the desired location.  The syringe size, the diameter and length of the tubing are other important factors that need 
to be considered. Upward displacement of the syringe pump results in a potential increase in the flow rate. With 
lower the infusion rates, the greater the relative bolus delivery of the drug. 110-113 Physicians need to be aware of 
these potential side effects and minimise their occurrence.  
Inotropes as molecules can be quite unstable if exposed to oxygen and diluted in infusion mixtures. A study on 
the stability of typical Dopamine and Dobutamine infusions made from adult formulations used in the NICU 
demonstrated two time points of significant changes in the concentration of Dopamine. Time point one was within 
the first 30 minutes of preparing the infusion and the second time point was after approximately 12 hours after the 
Dopamine infusion114. Drug concentrations fell by more than 7% which is outside the standard tolerance rate. It is 
therefore suggested to wait for 30 minutes before connecting a new infusion mixture to the neonate for infusion and 
to change dopamine infusions after 12 hours rather than every 24 hours. However, more frequent changing of 
inotrope infusions carries their own unwanted side effects and perhaps of more importance is the development of 
stable neonatal formulations.   
 
5. Future Directions  
 
The study of cardiotonic drugs in the neonate appears to be particularly challenging, especially in comparison to 
other areas of newborn care. There are no large randomized controlled trials evaluating the efficacy of various agents 
in the conditions outlined above. This is in stark contrast to the pediatric and adult population where large 
randomized controlled trials have been performed and have helped to inform practice. There are many potential 
reasons to explain this dearth of studies.  Since there are no neonatal specific formulations available, it is more 
challenging to perform studies in time sensitive situations. The incidence of the various conditions outlined seems to 
have decreased somewhat over time, which again makes it more challenging to enroll. Obtaining valid informed 
consent also remains a major hurdle to recruitment. A number of trials have met challenges in enrollment. These 
include a study on neonatal hypotension in extreme preterm neoantes115, a study of corticosteroid in cardiovascular 
instability in late preterm neoantes116 and a study of bosentan use in PPHN101.   These serve as a stark reminder of 
the challenges in conducting studies in this area and highlight the need for international collaborations, the 
importance of synergy between the FDA and EMA and the inclusion of industry in the conduct of such trials. The role 
of the International Neonatal Consortium is crucial to  facilitating this engagement and ensuring the foundations are 
established to finally try and answer some of these age old questions with clear and concise evidence.     
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Table 1. Overview of inotropes used for treatment of cardiovascular failure in neonates 
 
Drug name Receptors Proposed Physiological 
effects related to 
cardiovascular failure 
Dosing in newborns Administration 
Dopamine β1,β2 agonist, 
dopaminergic receptors  
Increases in HR, blood 
pressure, myocardial  
contractility and variable 
effects on SVR 
 
2-20 mcgg/kg/min Continuous infusion 
through central venous 
line 
Dobutamine α  and  β1 agonist, weak 
effect on β2 
Increases heart rate, 
myocardial contractility 
and stroke volume.  
 
5-20 mcg/kg/min Continuous infusion via 
peripheral or central 
venous line 
Epinephrine 𝛼1, α2, β1, β2 agonist Increases heart rate and 
stroke volume, variable 
effect on systemic 
vascular resistance  
0.05-1.0 mcg/kg/min Continuous infusion 
through central venous 
line 
Norepinephrine 𝛼1, α2, β1 agonist Increases heart rate, 
myocardial  contractility 
and vascular resistance 
causing vasoconstriction 
and increase in blood 
pressure.  
0.02-1 mcg/kg/ min  Continuous infusion 
through central venous 
line 
Levosimendon Calcium sensitizer 
activating sarcolemnal K-
sensitive adenosine 
triphosphate channel at 
cellular smooth muscle 
level 
Increases cardiac output 
and cardiac index. 
Vasodilatory effects, may 
cause decrease in heart 
rate and decrease in 
blood pressure  
0.1-0.2 mcg/kg/min Limited evidence after 
cardiac surgery. 
Milrinone  Type III phosphodiesterase 
inhibitor 
Decrease of pulmonary 
and systemic vascular 
resistance, may cause 
increase in heart rate and 
decrease in blood 
pressure. 
0.2-1 mcg/kg/min 
A bolus of 50 mcg/kg 
may be considered 
Continuous infusion 
through central venous 
line 
Vasopressin Vasopressin 1 receptors 
for vasoconstriction in 
systemic arteries 
Vasopressin 2 receptors 
for vasodilation in 
cerebral, renal and 
pulmonary circulation 
 
Increase in blood 
pressure, cardiac output. 
May decrease pulmonary 
vascular resistance. 
0.00001-0.003 
units/kg/min  
Continuous infusion 
through central venous 
line. Used as rescue 
treatment in persistent 
cardiovascular failure 
during sepsis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Some unanswered questions in  the treatment of cardiovascular failure and how echocardiography may influence the 
choice of agent used. Evidence supporting these interventions is limited and future clinical studies are essential.  
 
Conditions  Typical Echo findings   Possible agents  
 
Preterm transitional low blood 
pressure  
Normal 
 
Decreased myocardial contractility  
 
Presence of Large PDA  
 
Observation, low dose epinephrine or 
dopamine  
Low dose epinephrine or dobutamine  
 
Consider NSAID  
Persistent Pulmonary Hypertension 
  
Low systemic blood pressure  
 
Decresed RV function  
 
 
Consider epinephrine 
 
Consider doutmaine or Milrinone  
 
Monitor Blood pressure continuously  
Cardiac dysfunction in the setting of 
sepsis  
Decreased contractility  
 
Increased pulmonary artery 
 
Low systemic blood pressure  
 
Consider epinephrine 
 
Consider doutmaine or Milrinone  
 
Consider epinephrine, norepinephrine  
 
Cardiac dysfunction in the setting of 
therapeutic hypothermia  
Decreased contractility  
 
Increased pulmonary artery 
 
Low systemic blood pressure  
 
Consider epinephrine 
 
Consider doutmaine or Milrinone  
 
Consider epinephrine, norepinehrine 
 
  
 
 
 
Legends for Figure  
 
 
Figure 1: Monitoring of blood pressure (BP), blood flow, blood flow distribution, and vascular resistance. NIRS, Near-
infrared spectroscopy; OBF,organ blood flow; rSO2, regional tissue oxygen saturation. (From Soleymani S, Borzage M, 
Seri I: Hemodynamic monitoring in neonates: advances and challenges. J Perinatol 30:S38–S45, 2010. Used with 
permission from NaturePublishing Group.) 
 
Figure No. 2 The adapted brain circulation model: Overview of the hemodynamic effects on the brain. Interaction 
between the 3 processes (blood processes, vascular smooth muscle processes and tissue processes) and 3 
mechanisms (cerebral autoregulation, blood flow metabolism coupling and cerebral oxygen balance) as well as value 
of the appropriate monitoring tools. Reproduced with permission from Bentham 
